Study: NCT01181271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (conditioning for AUTO transplant)
Description: 0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (conditioning for AUTO transplant)
Description: Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (conditioning for AUTO transplant)
Description: Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna (prior to AUTO transplant)
Description: Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous (auto) peripheral blood stem cell transplantation
Description: Infusion of autologous peripheral blood stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (conditioning for ALLO Transplant)
Description: Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (conditioning for ALLO Transplant)
Description: Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-myeloablative allogeneic (allo) transplant
Description: Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2